Analysts Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.97

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $13.97.

Several equities analysts recently weighed in on VYGR shares. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Citigroup assumed coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group cut their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Finally, Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th.

Voyager Therapeutics Stock Down 2.4 %

VYGR opened at $3.65 on Thursday. The business’s fifty day simple moving average is $4.51 and its 200 day simple moving average is $5.65. Voyager Therapeutics has a 52 week low of $3.56 and a 52 week high of $10.66. The firm has a market cap of $201.51 million, a P/E ratio of 5.14 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $4.39 million during the quarter, compared to analysts’ expectations of $16.58 million. During the same period in the previous year, the firm posted $1.25 earnings per share. As a group, equities analysts expect that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in shares of Voyager Therapeutics during the fourth quarter worth about $29,000. Tower Research Capital LLC TRC grew its position in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock worth $31,000 after purchasing an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management grew its position in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after purchasing an additional 2,444 shares during the last quarter. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at approximately $60,000. Finally, Intech Investment Management LLC bought a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $74,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.